Wang YC, Wu MJ, Zhou SL, Li ZH. Protective effects of combined treatment with ciprofol and mild therapeutic hypothermia during cerebral ischemia-reperfusion injury. World J Clin Cases 2023; 11(3): 487-492 [PMID: 36793629 DOI: 10.12998/wjcc.v11.i3.487]
Corresponding Author of This Article
Zhi-Hui Li, MD, Doctor, Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan University; Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University. No. 37 Guoxue Lane, Wuhou District, Chengdu 640041, Sichuan Province, China. zhihuiliwt@163.com
Research Domain of This Article
Anesthesiology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2023; 11(3): 487-492 Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.487
Protective effects of combined treatment with ciprofol and mild therapeutic hypothermia during cerebral ischemia-reperfusion injury
Yi-Chao Wang, Meng-Jun Wu, Sheng-Liang Zhou, Zhi-Hui Li
Yi-Chao Wang, Sheng-Liang Zhou, Zhi-Hui Li, Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Yi-Chao Wang, Sheng-Liang Zhou, Zhi-Hui Li, Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Meng-Jun Wu, Department of Anesthesiology, Chengdu Women and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology, Chengdu 610041, Sichuan Province, China
Author contributions: Wang YC designed the study, conducted the data collection, and drafted the manuscript; Wu MJ performed the data collection and helped in the manuscript preparation and data analysis; Zhou SL helped in the manuscript preparation, grammatical revision, and data analysis; Li ZH performed the statistical analysis and helped in the data collection and in the manuscript preparation; All the authors approved the final version of the paper and agree to be accountable for all aspects of the work thereby ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Conflict-of-interest statement: We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled “Protective effects of combined treatment with Ciprofol and mild therapeutic hypothermia during cerebral ischemia-reperfusion injury”.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Hui Li, MD, Doctor, Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan University; Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University. No. 37 Guoxue Lane, Wuhou District, Chengdu 640041, Sichuan Province, China. zhihuiliwt@163.com
Received: May 6, 2022 Peer-review started: May 6, 2022 First decision: June 9, 2022 Revised: June 13, 2022 Accepted: January 5, 2022 Article in press: January 5, 2023 Published online: January 26, 2023 Processing time: 265 Days and 8.5 Hours
Abstract
Despite improvement in cardiopulmonary resuscitation (CPR) performance, cardiac arrest (CA) is still associated with poor prognosis. The high mortality rate is due to multi-organ dysfunction caused by cerebral ischemia and reperfusion injury (I/R). The guidelines for CPR suggest the use of therapeutic hypothermia (TH) as an effective treatment to decrease mortality and the only approach confirmed to reduce I/R injury. During TH, sedative agents (propofol) and analgesia agents (fentanyl) are commonly used to prevent shiver and pain. However, propofol has been associated with a number of serious adverse effects such as metabolic acidosis, cardiac asystole, myocardial failure, and death. In addition, mild TH alters the pharmacokinetics of agents (propofol and fentanyl) and reduces their systemic clearance. For CA patients undergoing TH, propofol can be overdosed, leading to delayed awakening, prolonged mechanical ventilation, and other subsequent complications. Ciprofol (HSK3486) is a novel anesthetic agent that is convenient and easy to administer intravenously outside the operating room. Ciprofol is rapidly metabolized and accumulates at low concentrations after continuous infusion in a stable circulatory system compared to propofol. Therefore, we hypothesized that treatment with HSK3486 and mild TH after CA could protect the brain and other organs.
Core Tip: Ciprofol (HSK3486) is a novel anesthetic agent that is convenient and easy to administer intravenously outside the operating room. Ciprofol is rapidly metabolized and accumulates at low concentrations after continuous infusion in a stable circulatory system compared to propofol. We hypothesize that HSK3486 can improve survival rates and achieve good neurological outcomes in cardiac arrest patients who receive therapeutic hypothermia.
